01093.HK
CSPC Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 8.93
+0.90%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 8.90
From 52W high−18.37%
Volume79.18M
Market capHKD 102.87B
P/E (TTM)11.7x
P/S (TTM)2.9x
Div yield3.25%
Key dataSep 18, 2026
Open
HKD 8.90
From 52W high
−18.37%
Volume
79.18M
Market cap
HKD 102.87B
ValuationView details →
P/E (Fwd)
15.4x
EV/EBITDA
7.2x
P/E (TTM)
11.7x
RSI (14)
48.6
MomentumView details →
1D Return
+0.90%
YTD Return
+5.93%
Similar companies
Latest newsMore news →
CSPC Group and AstraZeneca Continental signed a deal agreement on August 3 to establish a joint venture providing biopharmaceutical contract manufacturing organization services, with CSPC holding 51% and AstraZeneca Continental 49%; the concentration filing entered the public comment period on September 18, 2026.2d agoCSPC Pharmaceutical Group announced on September 16 that the Phase II clinical trial (SYH2069-003) of its SYH2069 injection for the treatment of adult type 2 diabetes has officially launched at its first study site in China.4d agoChina's National Medical Products Administration included CSPC Pharmaceutical Group's SYS 6010 in the breakthrough therapy designation list for recurrent or metastatic driver-gene-negative non-squamous non-small cell lung cancer that failed prior immunotherapy and platinum-based chemotherapy.4d ago